DexCom International — Revenue decreased by 2.3% to $359.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.0%, from $285.50M to $359.60M. Over 4 years (FY 2021 to FY 2025), International — Revenue shows an upward trend with a 22.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful international market penetration and growing global demand, while a decrease may indicate regulatory hurdles, competitive pressure, or economic headwinds in foreign markets.
This metric represents the total gross sales generated from geographic regions outside of the company's primary domestic...
Peers in the medical device sector typically report international revenue as a key indicator of global scalability and diversification away from domestic reimbursement risks.
dxcm_segment_international_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $133.60M | $160.60M | $181.10M | $177.60M | $185.20M | $196.20M | $208.80M | $215.50M | $254.70M | $261.40M | $265.40M | $267.80M | $272.40M | $292.30M | $310.70M | $285.50M | $316.10M | $357.40M | $368.10M | $359.60M |
| QoQ Change | — | +20.2% | +12.8% | -1.9% | +4.3% | +5.9% | +6.4% | +3.2% | +18.2% | +2.6% | +1.5% | +0.9% | +1.7% | +7.3% | +6.3% | -8.1% | +10.7% | +13.1% | +3.0% | -2.3% |
| YoY Change | — | — | — | — | +38.6% | +22.2% | +15.3% | +21.3% | +37.5% | +33.2% | +27.1% | +24.3% | +6.9% | +11.8% | +17.1% | +6.6% | +16.0% | +22.3% | +18.5% | +26.0% |